Please note: this product can only be supplied to registered research and development facilities, and may be used for in vitro research use only, not for administration to humans or animals.

EGFRvIII derived epitope.

EGFRvIII peptide is a peptide derived from the fusion junction of epidermal growth factor receptor variant III (EGFRvIII), a variant of EGFR with amino acids 6 273 deleted. This spontaneously occurring alteration is found in a high percentage of primary human brain, breast, lung and ovarian tumours making EGFRvIII an ideal target of immunotherapy in EGFRvIII-expressing tumours. EGFRvIII peptide was identified from a number of candidates as the most immunogenic epitope for major histocompatibility complex I (MHC I) binding to induce tumour specific immune responses. In a glioblastoma mouse brain tumour model EGFRvIII peptide co-administered with the toll-like receptor 5 (TLR5) adjuvant Flagellin B induces an increase in CD8 ?+ ?T cells and a decrease in Treg cells, inducing tumour apoptosis, inhibiting tumour growth and increasing survival.

Please contact us for availability.